الفهرس 
Renal cell carcinomaOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
please write abstract.Renal cell carcinoma (RCC) is the most common cancer of the kidney. Approximately 20%–30% of patients presented with metastatic disease and 70–80% of patients presented with localized or locally advanced disease at the time of diagnosis, which is potentially curable by radical surgical resection alone Sunitinib is an oral small molecular tyrosine kinase inhibitor that was rationally designed and chosen for its high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kinases (RTKs) , vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).